Trade
Basic
Futures
Futures
Hundreds of contracts settled in USDT or BTC
TradFi
Gold
Trade global traditional assets with USDT in one place
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Futures Kickoff
Get prepared for your futures trading
Futures Events
Participate in events to win generous rewards
Demo Trading
Use virtual funds to experience risk-free trading
Earn
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and enjoy airdrop rewards!
Futures Points
Earn futures points and claim airdrop rewards
Investment
Simple Earn
Earn interests with idle tokens
Auto-Invest
Auto-invest on a regular basis
Dual Investment
Buy low and sell high to take profits from price fluctuations
Soft Staking
Earn rewards with flexible staking
Crypto Loan
0 Fees
Pledge one crypto to borrow another
Lending Center
One-stop lending hub
VIP Wealth Hub
Customized wealth management empowers your assets growth
Private Wealth Management
Customized asset management to grow your digital assets
Quant Fund
Top asset management team helps you profit without hassle
Staking
Stake cryptos to earn in PoS products
Smart Leverage
New
No forced liquidation before maturity, worry-free leveraged gains
GUSD Minting
Use USDT/USDC to mint GUSD for treasury-level yields
More
Trending Topics
View More313.6K Popularity
102.94K Popularity
418.7K Popularity
3.76K Popularity
117.87K Popularity
Pin
Incyte Corp. (INCY) Reports Q4 2025 Revenue Growth of 28% to $1.51B Driven by Jakafi and Opzelura Sales
Incyte Corporation reported a significant 28% increase in Q4 2025 revenue, reaching $1.51 billion, with full-year sales at $5.14 billion, primarily fueled by strong sales of Jakafi and Opzelura. The company’s core business, excluding Jakafi, grew by 53% year-over-year in the final quarter, driven by its hematology and oncology franchise. Incyte aims to nearly double its business size through innovation and strategic development, focusing on next-gen treatments and expecting continued core business growth in 2026.